SCHEMBL16007653

SCHEMBL16007653

O=C(Nc1nnc[nH]1)c1cccnc1NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 3/20 0.47
DRD2 P14416 2/20 0.47
DRD3 P35462 2/20 0.47
SIGMAR1 Q99720 5/20 0.47
JAK2 O60674 4/20 0.46
JAK1 P23458 4/20 0.46
TYK2 P29597 4/20 0.46
JAK3 P52333 4/20 0.46
POLB P06746 1/20 0.45
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
FLT3 P36888 1/20 0.43
TYRO3 Q06418 1/20 0.43
MERTK Q12866 1/20 0.43
GAS6 Q14393 1/20 0.43
ACHE P22303 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16007664 0.82 POLB (0.59) DRD4DRD2DRD3SIGMAR1JAK2
SCHEMBL16007213 0.81 SIGMAR1 (0.57) DRD4DRD2DRD3SIGMAR1POLB
SCHEMBL16017733 0.81 DRD4 (0.57) DRD4DRD2DRD3SIGMAR1POLB
SCHEMBL16007613 0.80 SIGMAR1 (0.56) DRD4DRD2DRD3SIGMAR1POLB
SCHEMBL16017741 0.79 DRD4 (0.48) DRD4DRD2DRD3SIGMAR1JAK2
SCHEMBL16007647 0.79 ACKR3 (0.56) DRD4SIGMAR1
SCHEMBL16007709 0.79 POLB (0.50) DRD4DRD2DRD3SIGMAR1POLB
SCHEMBL16007674 0.79 LTA4H (0.58) DRD4DRD2DRD3POLBKMT2A
SCHEMBL16007371 0.79 SIGMAR1 (0.54) DRD4DRD2DRD3SIGMAR1JAK2
SCHEMBL16017723 0.79 SIGMAR1 (0.54) DRD4DRD2DRD3SIGMAR1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 US claimed
US-20140256711-A1 Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2014-09-11 US claimed
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 US disclosed
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 US disclosed
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 US disclosed
US-20140256711-A1 Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256711-A1 Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same VEGFA, EDF1, FLT1 DRD4 4763/4885DRD2 4813/4885DRD3 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.